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Introduction {#bjs10233-sec-0005}
============

A variety of monitoring strategies have been used in patients who have had potentially curative surgery for primary colorectal cancer. Their aim has been to detect active disease before it is symptomatic or clinically evident so that further treatment can be instigated. Five randomized trials published from 1995 to 1998 were the subject of a systematic review and meta‐analysis published in 2002[1](#bjs10233-bib-0001){ref-type="ref"}. Intensive follow‐up was associated with significantly earlier detection by a mean of 8·5 months. The combined risk ratio was 0·81 (95 per cent c.i. 0·70 to 0·94) in favour of intensive follow‐up. However, the authors found that methods were poorly reported and concluded that 'large trials are required to identify which components of intensive follow up are most beneficial'. Since then, three large trials[2](#bjs10233-bib-0002){ref-type="ref"}, [3](#bjs10233-bib-0003){ref-type="ref"}, [4](#bjs10233-bib-0004){ref-type="ref"} of intensified monitoring have reported. An updated search, systematic review and meta‐analysis have been undertaken to examine the effect of these programmes on overall survival including all randomized studies identified.

Methods {#bjs10233-sec-0006}
=======

A systematic review of literature on follow‐up strategies for patients with colorectal cancer was conducted according to the PRISMA guidelines[5](#bjs10233-bib-0005){ref-type="ref"} and is registered in PROSPERO (CRD42015026835). This study was based on predefined eligibility criteria and conducted according to a predefined methodological approach.

Search strategy {#bjs10233-sec-0007}
---------------

An extensive search for published articles was conducted in collaboration with a medical librarian. The electronic databases of MEDLINE (Ovid), Embase, the Cochrane Library and Web of Science, Scopus, CINAHL (EBSCO), PubMed publisher, Google Scholar, LILACS, SciELO and ProQuest were searched. The searches identified four index terms: large intestinal cancer, surgery, periodical surveillance and mortality or survival. Appropriate thesaurus terms (for MEDLINE, Embase and CINAHL) and keywords in the title and/or abstract were combined by Boolean logical operators, and adapted to the appropriate syntax of each database. The reference lists of reviews and included studies were cross‐checked.

Selection of studies {#bjs10233-sec-0008}
--------------------

Papers were screened by two independent investigators, arbitrated by a third reviewer. Data were extracted from studies reporting randomly assigned groups of patients in surveillance protocols of differing intensity. Only studies conducted in humans and written in English were included. Studies with inadequate data on survival for meta‐analysis were retained for textual summaries of the design, findings and conclusions.

Outcome measures {#bjs10233-sec-0009}
----------------

The primary outcome was the overall survival difference between the existing monitoring strategy compared with a more intensive monitoring strategy.

Quality control {#bjs10233-sec-0010}
---------------

Studies were checked independently for quality using the Cochrane risk of bias tool[6](#bjs10233-bib-0006){ref-type="ref"}. The authors of all studies were approached for further information[7](#bjs10233-bib-0007){ref-type="ref"}.

Data extraction {#bjs10233-sec-0011}
---------------

Data were extracted by one researcher and checked independently by a second reviewer. A third investigator resolved any discrepancies. Patient numbers, baseline characteristics, all‐cause mortality, cancer‐specific mortality and recurrence rates were retrieved for each study.

Overall survival data were extracted as event rates reported for more *versus* less intensive monitoring arms of all randomized comparisons. Odds ratios (ORs) and their variances were calculated. Hazard ratios (HRs) were derived from Kaplan--Meier curves. The method described by Williamson and colleagues[8](#bjs10233-bib-0008){ref-type="ref"} was used to estimate a logarithmic HR with corresponding variance when the number of patients at risk was given at each time point. If these data were not provided, the method of Parmar *et al*.[9](#bjs10233-bib-0009){ref-type="ref"} was used. The overall HR with 95 per cent c.i. was estimated using an inverse variance‐weighted average[10](#bjs10233-bib-0010){ref-type="ref"}.

Statistical analysis {#bjs10233-sec-0012}
--------------------

Review Manager (RevMan) for Windows® version 5.3 (Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark) was used for meta‐analysis. Funnel plots were used to investigate publication bias. Heterogeneity among the included studies was analysed by means of the *I* ^2^ measure[11](#bjs10233-bib-0011){ref-type="ref"}. A random‐effects meta‐analysis was performed after exclusion of trials with a high risk of bias.

ORs were also used to summarize observed effects, and a random‐effects logistic regression model was used to provide an overall estimate of an effect for subsets of studies defined by the chosen method of enhanced detection. Subgroup analyses of outcome were performed to account for different diagnostic tests used during follow‐up in different randomized trials. Studies were grouped as follows: any site of recurrence; endoscopically detected recurrence; or the clinical setting of follow‐up. Sensitivity analyses were performed to identify studies that were estimated to have a high risk of bias.

Meta‐analysis was undertaken and forest plots were constructed for all trials that reached the criteria for inclusion. Since the previous meta‐analysis calling for large trials[1](#bjs10233-bib-0001){ref-type="ref"}, there have been three large multicentre trials, published in 2006, 2014 and 2016[2](#bjs10233-bib-0002){ref-type="ref"}, [3](#bjs10233-bib-0003){ref-type="ref"}, [4](#bjs10233-bib-0004){ref-type="ref"} relating to policies of earlier detection of patients suitable for the growing practice of metastasectomy[12](#bjs10233-bib-0012){ref-type="ref"}, [13](#bjs10233-bib-0013){ref-type="ref"}, [14](#bjs10233-bib-0014){ref-type="ref"}. The analysis was repeated in this subset of trials.

Results {#bjs10233-sec-0013}
=======

Among 7081 publications, there were 22 relevant articles[2](#bjs10233-bib-0002){ref-type="ref"}, [3](#bjs10233-bib-0003){ref-type="ref"}, [4](#bjs10233-bib-0004){ref-type="ref"}, [15](#bjs10233-bib-0015){ref-type="ref"}, [16](#bjs10233-bib-0016){ref-type="ref"}, [17](#bjs10233-bib-0017){ref-type="ref"}, [18](#bjs10233-bib-0018){ref-type="ref"}, [19](#bjs10233-bib-0019){ref-type="ref"}, [20](#bjs10233-bib-0020){ref-type="ref"}, [21](#bjs10233-bib-0021){ref-type="ref"}, [22](#bjs10233-bib-0022){ref-type="ref"}, [23](#bjs10233-bib-0023){ref-type="ref"}, [24](#bjs10233-bib-0024){ref-type="ref"}, [25](#bjs10233-bib-0025){ref-type="ref"}, [26](#bjs10233-bib-0026){ref-type="ref"}, [27](#bjs10233-bib-0027){ref-type="ref"}, [28](#bjs10233-bib-0028){ref-type="ref"}, [29](#bjs10233-bib-0029){ref-type="ref"}, [30](#bjs10233-bib-0030){ref-type="ref"}, [31](#bjs10233-bib-0031){ref-type="ref"}, [32](#bjs10233-bib-0032){ref-type="ref"}, [33](#bjs10233-bib-0033){ref-type="ref"} describing 16 randomized comparisons (*Fig*. [1](#bjs10233-fig-0001){ref-type="fig"}). Text summaries of all 16 randomized trials are provided in *Appendix S1* (supporting information). Five studies were excluded because there were no survival data available for analysis[28](#bjs10233-bib-0028){ref-type="ref"}, [31](#bjs10233-bib-0031){ref-type="ref"} or they had high risk of bias[18](#bjs10233-bib-0018){ref-type="ref"}, [21](#bjs10233-bib-0021){ref-type="ref"}, [23](#bjs10233-bib-0023){ref-type="ref"} (*Table*  [1](#bjs10233-tbl-0001){ref-type="table-wrap"}). The remaining 11 studies provided data on overall survival suitable for meta‐analysis and, of these, seven[2](#bjs10233-bib-0002){ref-type="ref"}, [3](#bjs10233-bib-0003){ref-type="ref"}, [4](#bjs10233-bib-0004){ref-type="ref"}, [16](#bjs10233-bib-0016){ref-type="ref"}, [17](#bjs10233-bib-0017){ref-type="ref"}, [22](#bjs10233-bib-0022){ref-type="ref"}, [30](#bjs10233-bib-0030){ref-type="ref"} included methods that allowed detection of metastases (*Table*  [2](#bjs10233-tbl-0002){ref-type="table-wrap"}, *Figs*  [2](#bjs10233-fig-0002){ref-type="fig"} and [3](#bjs10233-fig-0003){ref-type="fig"}). Two studies[20](#bjs10233-bib-0020){ref-type="ref"}, [27](#bjs10233-bib-0027){ref-type="ref"} were confined to endoscopic examination following more or less intensive protocols (*Table*  [3](#bjs10233-tbl-0003){ref-type="table-wrap"}). Two studies[24](#bjs10233-bib-0024){ref-type="ref"}, [25](#bjs10233-bib-0025){ref-type="ref"} followed the same protocol in each arm but were administered in hospital by a specialist or in a general practice setting.

![Flow chart showing selection of trials for review](BJS-103-1259-g001){#bjs10233-fig-0001}

###### 

Studies excluded from meta‐analysis

  Trial                                                        Start   End    Tests             No. of centres   No. of patients randomized   Reason for exclusion
  ------------------------------------------------------------ ------- ------ ----------------- ---------------- ---------------------------- ------------------------------------------------------------------
  Barillari et al. [18](#bjs10233-bib-0018){ref-type="ref"}    1980    1990   Colonoscopy       1                212                          Inadequate survival data
  Schoemaker et al. [21](#bjs10233-bib-0021){ref-type="ref"}   1984    1990   CT                1                325                          Potential lack of allocation concealment
                                                                              Colonoscopy                                                     
  Secco et al. [23](#bjs10233-bib-0023){ref-type="ref"}        1988    1996   CEA               1                337                          Reviewers could not reconcile conclusions with randomized groups
                                                                              Colonoscopy                                                     
                                                                              Ultrasonography                                                 
  COLOFOL[28](#bjs10233-bib-0028){ref-type="ref"}              2006    2011   CEA               24               2571                         Results not yet published
                                                                              CT                                                              
  CEAwatch[31](#bjs10233-bib-0031){ref-type="ref"}             2010    2012   CEA               11               3223                         No outcome data reported

CEA, carcinoembryonic antigen.

###### 

Details of the seven trials included in meta‐analysis

  Trial                                                               Start   End    Tests[\*](#bjs10233-note-0003){ref-type="fn"}   No. of centres   No. of patients randomized                   Authors\' conclusion
  ------------------------------------------------------------------- ------- ------ ----------------------------------------------- ---------------- -------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  CEASL[30](#bjs10233-bib-0030){ref-type="ref"}                       1982    1993   CEA                                             58               216[†](#bjs10233-note-0004){ref-type="fn"}   '... highly unlikely that any survival advantage would be demonstrated for patients undergoing second‐look surgery'
  Ohlsson et al. [17](#bjs10233-bib-0017){ref-type="ref"}             1983    1986   Endoscopy                                       2                107                                          'Intense follow‐up ... did not prolong survival in this study'
                                                                                     CT                                                                                                            
                                                                                     CEA                                                                                                           
  Pietra et al. [22](#bjs10233-bib-0022){ref-type="ref"}              1987    1990   CEA                                             1                207                                          'Our data support use of an intense follow‐up plan after primary resection of large‐bowel cancer, at least in patients with rectal cancer'
                                                                                     Ultrasonography                                                                                               
                                                                                     CT                                                                                                            
                                                                                     Chest X‐ray                                                                                                   
                                                                                     Colonoscopy                                                                                                   
  Mäkelä et al. [16](#bjs10233-bib-0016){ref-type="ref"}              1988    1990   CEA                                             1                106                                          'Earlier detection of recurrent carcinoma by intensified follow‐up does not lead to increased re‐resectability or improved 5‐year survival'
                                                                                     Chest X‐ray                                                                                                   
                                                                                     CT                                                                                                            
  Rodriguez ‐Moranta et al. [2](#bjs10233-bib-0002){ref-type="ref"}   1997    2001   CEA                                             3                259                                          'there was no difference in the probability of overall survival'
                                                                                     Colonoscopy                                                                                                   
                                                                                     CT                                                                                                            
                                                                                     Ultrasonography                                                                                               
                                                                                     Chest X‐ray                                                                                                   
  GILDA[4](#bjs10233-bib-0004){ref-type="ref"}                        1998    2006   CEA                                             41               1228                                         'early diagnosis of cancer recurrence is not associated with overall survival benefit'
                                                                                     Colonoscopy                                                                                                   
                                                                                     Chest X‐ray                                                                                                   
                                                                                     Ultrasonography                                                                                               
  FACS[3](#bjs10233-bib-0003){ref-type="ref"}                         2003    2009   CEA                                             39               1202                                         'The number of deaths was not significantly different in the combined intensive monitoring groups vs the minimum follow‐up group'
                                                                                     CT                                                                                                            

There were more tests, more frequent tests, or both in the group with more intensive monitoring.

If the carcinoembryonic antigen (CEA) level was raised according to study criteria, patients were randomized to have this revealed to the clinical team or not.

![Forest plot showing hazard ratios for death in seven randomized comparisons of more and less intensive follow‐up from which hazard ratios could be derived. An inverse‐variance random‐effects model was used to produce an overall estimated hazards ratio. Hazard ratios are shown with 95 per cent confidence intervals. The studies are ordered according to the year of the start of the inclusion. CEASL is dominant because the weight of the study is dependent on the follow‐up time, number of events and number of patients in each treatment arm. The Kaplan--Meier curve in CEASL is plotted up to 25 years. The point estimate in favour of more intensive monitoring in studies by Rodriguez‐Moranta et al. [2](#bjs10233-bib-0002){ref-type="ref"} and Pietra and colleagues[22](#bjs10233-bib-0022){ref-type="ref"} was attributed by the authors to detection by endoscopy and successful treatment of recurrent rectal carcinoma](BJS-103-1259-g002){#bjs10233-fig-0002}

![Forest plot showing odds ratios for death in seven randomized comparisons of more and less intensive follow‐up. A Mantel--Haenszel random‐effects model was used to produce an overall estimated odds ratio. Odds ratios are shown with 95 per cent confidence intervals](BJS-103-1259-g003){#bjs10233-fig-0003}

###### 

Details of single‐centre trials confined to endoscopic methods of monitoring

  Trial                                                      Start   End    Tests         No. of patients   Authors\' conclusions
  ---------------------------------------------------------- ------- ------ ------------- ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Kjeldsen et al. [20](#bjs10233-bib-0020){ref-type="ref"}   1983    1994   Colonoscopy   597               'no improvement in overall survival or in cancer‐related survival'
  Wang et al. [27](#bjs10233-bib-0027){ref-type="ref"}       1995    2001   Colonoscopy   326               There was higher detection of asymptomatic recurrence and more operations but the authors concluded that more intensive colonoscopy 'did not improve overall survival'

Detailed protocols for investigations used for monitoring and their frequency are summarized in Appendix S2 (supporting information).

Quality of studies: risk of bias {#bjs10233-sec-0014}
--------------------------------

Three studies were found to have a high risk of bias in at least one domain (Table  [4](#bjs10233-tbl-0004){ref-type="table-wrap"}). Blinding of participants and personnel (performance bias) was not possible and so there is a remaining risk of bias. Blinding of outcome assessment (detection bias) is not relevant for the main outcome measure, which is death/survival.

###### 

Risk of bias

  Reference                                                          Randomization method                          Allocation concealment                        Incomplete outcome assessment                  Selective reporting  
  ------------------------------------------------------------------ --------------------------------------------- --------------------------------------------- ---------------------------------------------- -----------------------
  CEASL[30](#bjs10233-bib-0030){ref-type="ref"}                      Low                                           Low                                           Low                                            Low
  Ohlsson et al. [17](#bjs10233-bib-0017){ref-type="ref"}            Unclear                                       Unclear                                       Low                                            Low
  Pietra et al. [22](#bjs10233-bib-0022){ref-type="ref"}             Unclear                                       Unclear                                       Low                                            Low
  Rodriguez‐Moranta et al. [2](#bjs10233-bib-0002){ref-type="ref"}   Low                                           Low                                           Low                                            Low
  Mäkelä et al. [16](#bjs10233-bib-0016){ref-type="ref"}             Unclear                                       Unclear                                       Low                                            Low
  GILDA[4](#bjs10233-bib-0004){ref-type="ref"}                       Unclear                                       Low                                           Low                                            Low
  FACS[3](#bjs10233-bib-0003){ref-type="ref"}                        Unclear                                       Unclear                                       Low                                            Low
  Kjeldsen et al. [20](#bjs10233-bib-0020){ref-type="ref"}           Unclear                                       Unclear                                       High[\*](#bjs10233-note-0005){ref-type="fn"}   Low
  Wang et al. [27](#bjs10233-bib-0027){ref-type="ref"}               Unclear                                       Low                                           Unclear                                        Low
  Wattchow et al. [24](#bjs10233-bib-0024){ref-type="ref"}           Unclear                                       Low                                           Low                                            Low
  Augestad et al. [25](#bjs10233-bib-0025){ref-type="ref"}           Low                                           Low                                           Low                                            Low
  Schoemaker et al. [21](#bjs10233-bib-0021){ref-type="ref"}         Low                                           High[†](#bjs10233-note-0006){ref-type="fn"}   Unclear                                        Low
  Secco et al. [23](#bjs10233-bib-0023){ref-type="ref"}              High[‡](#bjs10233-note-0007){ref-type="fn"}   Unclear                                       High[§](#bjs10233-note-0008){ref-type="fn"}    Low
  CEAwatch[31](#bjs10233-bib-0031){ref-type="ref"}                   Low                                           Low                                           Low                                            Low

Groups not balanced (290 : 307); drop‐outs may not be included in assessment.

Cards not in envelopes; groups not balanced (167 : 158).

Method unclear; groups not balanced (108 : 84 and 84 : 61).

Patients excluded from survival rather than censored if lost to follow‐up. COLOFOL has not reported so cannot be assessed; the methods of assignment were not described by Barillari et al. [18](#bjs10233-bib-0018){ref-type="ref"}, and this did not appear to be a true randomized comparison.

Effectiveness of more intensive monitoring in advancing detection {#bjs10233-sec-0015}
-----------------------------------------------------------------

For studies in which the time difference in detection was given (9 of 16) the advance in diagnosis was 2--30 months, with a median of 10 (i.q.r. 5--24) months (Table [5](#bjs10233-tbl-0005){ref-type="table-wrap"}).

###### 

Cancer recurrence rates and difference in time to detection in RCTs of monitoring strategies following potentially curative resection of colorectal cancer

  Reference                                                  Recruitment   Methods tested[\*](#bjs10233-note-0009){ref-type="fn"}   Recurrence (%)                              Detection advance (months)                  
  ---------------------------------------------------------- ------------- -------------------------------------------------------- ------------------------------------------- ------------------------------------------- ----
  CEASL[30](#bjs10233-bib-0030){ref-type="ref"}              1982--1993    CEA                                                      --[†](#bjs10233-note-0010){ref-type="fn"}   --[†](#bjs10233-note-0010){ref-type="fn"}   11
  Ohlsson et al. [17](#bjs10233-bib-0017){ref-type="ref"}    1983--1986    CEA, CT, endoscopy                                                                                                                               4
  Kjeldsen et al. [20](#bjs10233-bib-0020){ref-type="ref"}   1983--1984    Endoscopy                                                26                                          26                                          9
  Mäkelä et al. [16](#bjs10233-bib-0016){ref-type="ref"}     1988--1990    CT                                                       42                                          39                                          5
  Wang et al. [27](#bjs10233-bib-0027){ref-type="ref"}       1995--2001    Endoscopy                                                8                                           11                                          13
  GILDA[4](#bjs10233-bib-0004){ref-type="ref"}               1998--2006    CT, endoscopy, liver ultrasonography                     15                                          13                                          6
  Wattchow et al. [24](#bjs10233-bib-0024){ref-type="ref"}   1998--2001    Setting: surgeon‐ or GP‐led                                                                                                                      2
  FACS[3](#bjs10233-bib-0003){ref-type="ref"}                                                                                                                                                                               
  CEA                                                        2003--2009    CEA                                                      22                                          14                                          24
  CT                                                         2004--2009    CT                                                       20                                          14                                          30
  CEA and CT                                                 2005--2009    CEA, CT                                                  17·5                                        14                                          24

Only tests that were not the same in the two groups.

Only a minority of patients meeting the stringent carcinoembryonic antigen (CEA) criteria were randomized, so detection was similar in both randomized groups and effectively 100 per cent.

Main outcome measure: effectiveness in improving survival {#bjs10233-sec-0016}
---------------------------------------------------------

The numbers of randomized patients and the numbers of all detection events and deaths are given in Tables  [6](#bjs10233-tbl-0006){ref-type="table-wrap"}, [7](#bjs10233-tbl-0007){ref-type="table-wrap"}, [8](#bjs10233-tbl-0008){ref-type="table-wrap"}. The principal result derives from the meta‐analysis of HRs based on trials from which these could be estimated. The summary HR estimate was 0·98 (95 per cent c.i. 0·87 to 1·11), with no evidence of significant heterogeneity (I ^2^ = 14 per cent) (Fig.  [2](#bjs10233-fig-0002){ref-type="fig"}).

###### 

All‐cause mortality rates in randomized trials

                                                                                          All‐cause mortality   
  --------------------------------------------------------------------------------------- --------------------- ---------------------
  CEASL[30](#bjs10233-bib-0030){ref-type="ref"}                                           91 of 108 (84·3)      88 of 108 (81·5) 
  Mäkelä et al. [16](#bjs10233-bib-0016){ref-type="ref"}                                  23 of 52 (44)         27 of 54 (50) 
  Ohlsson et al. [17](#bjs10233-bib-0017){ref-type="ref"}                                 15 of 53 (28)         22 of 54 (41) 
  Kjeldsen et al. [20](#bjs10233-bib-0020){ref-type="ref"}                                88 of 290 (30·3)      100 of 307 (32·6) 
  Pietra et al. [22](#bjs10233-bib-0022){ref-type="ref"}                                  28 of 104 (26·9)      43 of 103 (41·7) 
  Schoemaker et al. [21](#bjs10233-bib-0021){ref-type="ref"}                              43 of 167 (25·7)      55 of 158 (34·8) 
  Secco et al. [23](#bjs10233-bib-0023){ref-type="ref"}                                   73 of 192 (38·0)      81 of 145 (55·9) 
  GILDA[4](#bjs10233-bib-0004){ref-type="ref"}                                            113 of 615 (18·4)     105 of 613 (17·1) 
  Rodriguez‐Moranta et al. [2](#bjs10233-bib-0002){ref-type="ref"}                        21 of 127 (16·5)      27 of 132 (20·5) 
  Wattchow et al. [24](#bjs10233-bib-0024){ref-type="ref"}                                32 of 76 (42)         25 of 81 (31) 
  Wang et al. [27](#bjs10233-bib-0027){ref-type="ref"}                                    42 of 165 (25·5)      50 of 161 (31·1) 
  Augestad et al. [25](#bjs10233-bib-0025){ref-type="ref"}                                1 of 55 (2)           4 of 55 (7) 
  FACS[3](#bjs10233-bib-0003){ref-type="ref"}, [34](#bjs10233-bib-0034){ref-type="ref"}   164 of 901 (18·2)     48 of 301 (15·9) 
  CEAwatch[31](#bjs10233-bib-0031){ref-type="ref"}                                        n.r.                  n.r. 
  COLOFOL[28](#bjs10233-bib-0028){ref-type="ref"}                                         n.r.                  n.r. 
  Total                                                                                   734 of 2905 (25·3)    675 of 2272 (29·7) 

Values in parentheses are percentages. n.r., Not reported.

###### 

Local recurrence rates in randomized trials

                                                                                                       Local recurrence    
  ---------------------------------------------------------------------------------------------------- ------------------- --------------------
  CEASL[30](#bjs10233-bib-0030){ref-type="ref"}                                                        n.r.                n.r. 
  Mäkelä et al. [16](#bjs10233-bib-0016){ref-type="ref"}                                               12 of 52 (23)       11 of 54 (20) 
  Ohlsson et al. [17](#bjs10233-bib-0017){ref-type="ref"}                                              11 of 53 (21)       8 of 54 (15) 
  Kjeldsen et al. [19](#bjs10233-bib-0019){ref-type="ref"}, [20](#bjs10233-bib-0020){ref-type="ref"}   49 of 290 (16·9)    42 of 307 (13·7) 
  Pietra et al. [22](#bjs10233-bib-0022){ref-type="ref"}                                               20 of 104 (19·2)    26 of 103 (25·2) 
  Schoemaker et al. [21](#bjs10233-bib-0021){ref-type="ref"}                                           7 of 167 (4·2)      11 of 158 (7·0) 
  Secco et al. [23](#bjs10233-bib-0023){ref-type="ref"}                                                41 of 192 (21·4)    35 of 145 (24·1) 
  GILDA[4](#bjs10233-bib-0004){ref-type="ref"}                                                         36 of 615 (5·9)     32 of 613 (5·2) 
  Rodriguez‐Moranta et al. [2](#bjs10233-bib-0002){ref-type="ref"}                                     11 of 127 (8·7)     13 of 132 (10·1) 
  Wattchow et al. [24](#bjs10233-bib-0024){ref-type="ref"}                                             n.r.                n.r. 
  Wang et al. [27](#bjs10233-bib-0027){ref-type="ref"}                                                 10 of 165 (6·1)     12 of 161 (7·5) 
  Augestad et al. [25](#bjs10233-bib-0025){ref-type="ref"}                                             6 of 55 (11)        8 of 55 (15) 
  FACS[3](#bjs10233-bib-0003){ref-type="ref"}, [34](#bjs10233-bib-0034){ref-type="ref"}                35 of 901 (3·9)     6 of 301 (2·0) 
  CEAwatch[31](#bjs10233-bib-0031){ref-type="ref"}                                                     31 of 316 (9·8)     13 of 1182 (1·1) 
  COLOFOL[28](#bjs10233-bib-0028){ref-type="ref"}                                                      n.r                 n.r. 
  Total                                                                                                269 of 3037 (8·9)   217 of 3265 (6·6) 

Values in parentheses are percentages. n.r., Not reported.

###### 

Distant recurrence rates in randomized trials

                                                                                                       Distant recurrence   
  ---------------------------------------------------------------------------------------------------- -------------------- ----------------------
  CEASL[30](#bjs10233-bib-0030){ref-type="ref"}                                                        32 of 108 (29·6)     n.r.
  Mäkelä et al. [16](#bjs10233-bib-0016){ref-type="ref"}                                               10 of 52 (19)        10 of 54 (19)
  Ohlsson et al. [17](#bjs10233-bib-0017){ref-type="ref"}                                              9 of 53 (17)         12 of 54 (22)
  Kjeldsen et al. [19](#bjs10233-bib-0019){ref-type="ref"}, [20](#bjs10233-bib-0020){ref-type="ref"}   34 of 290 (11·7)     48 of 307 (15·6)
  Pietra et al. [22](#bjs10233-bib-0022){ref-type="ref"}                                               15 of 104 (14·4)     21 of 103 (20·4)
  Schoemaker et al. [21](#bjs10233-bib-0021){ref-type="ref"}                                           n.r.                 n.r.
  Secco et al. [23](#bjs10233-bib-0023){ref-type="ref"}                                                38 of 192 (19·8)     47 of 145 (32·4)
  GILDA[4](#bjs10233-bib-0004){ref-type="ref"}                                                         59 of 615 (9·6)      42 of 613 (6·9)
  Rodriguez‐Moranta et al. [2](#bjs10233-bib-0002){ref-type="ref"}                                     20 of 127 (15·7)     19 of 132 (14·4)
  Wattchow et al. [24](#bjs10233-bib-0024){ref-type="ref"}                                             n.r.                 n.r.
  Wang et al. [27](#bjs10233-bib-0027){ref-type="ref"}                                                 n.r.                 n.r.
  Augestad et al. [25](#bjs10233-bib-0025){ref-type="ref"}                                             3 of 55 (5)          4 of 55 (7)
  FACS[3](#bjs10233-bib-0003){ref-type="ref"}, [34](#bjs10233-bib-0034){ref-type="ref"}                39 of 901 (4·3)      18 of 301 (6·0)
  CEAwatch[31](#bjs10233-bib-0031){ref-type="ref"}                                                     n.r.                 n.r.
  COLOFOL[28](#bjs10233-bib-0028){ref-type="ref"}                                                      n.r.                 n.r.
  Total                                                                                                259 of 2497 (10·4)   221 of 1764 (12·5)  

Values in parentheses are percentages. n.r., Not reported.

The meta‐analysis of simple ORs for death based on the same seven studies is shown in Fig.  [3](#bjs10233-fig-0003){ref-type="fig"}; the summary OR for death was 0·91 (95 per cent c.i. 0·71 to 1·16). ORs were derived from the percentage of deaths in each arm at the time of reporting, whereas the HR gives an estimate of the overall relative survival, which is more relevant when considering a time‐to‐event endpoint.

A meta‐analysis of ORs for death is also shown for two studies in which the difference in monitoring was confined to endoscopy, and two studies for which the difference was between a hospital/specialist setting and a general practice setting (Fig. [4](#bjs10233-fig-0004){ref-type="fig"}).

![Forest plot for death in two studies in which the difference in monitoring was confined to endoscopy, and two studies for which the difference was between a hospital/specialist setting and a general practice setting. A Mantel--Haenszel random‐effects model was used to produce an overall estimated odds ratio. Odds ratios are shown with 95 per cent confidence intervals](BJS-103-1259-g004){#bjs10233-fig-0004}

There is a residual possibility of publication bias as demonstrated in the asymmetry of the forest plot for the main analysis (*Fig*. [2](#bjs10233-fig-0002){ref-type="fig"}) and the funnel plot (*Fig*. [5](#bjs10233-fig-0005){ref-type="fig"}). Because of the proportion of the weight accredited by RevMan to CEASL (Carcino‐Embryonic Antigen Second Look), and because in this study the monitoring was solely by CEA and not CT, a sensitivity analysis was performed after exclusion of CEASL. This did not alter the conclusion (HR 0·92, 0·76 to 1·36)

![Funnel plot of studies included in meta‐analysis. Reference numbers are shown](BJS-103-1259-g005){#bjs10233-fig-0005}

The three trials reporting from 2006 to 2016 were larger, multicentre, better quality studies and contributed 2689 (80·9 per cent) of the 3325 patients included in the overall meta‐analysis (Fig. [2](#bjs10233-fig-0002){ref-type="fig"}). The summary estimated HR from a meta‐analysis of these trials was 1·05 (0·87 to 1·27) (Fig.  [6](#bjs10233-fig-0006){ref-type="fig"}).

![Subset analysis of three large multicentre RCTs published in 2006, 2014 and 2016, which included 80·9 per cent of all patients in the full systematic review. A random‐effects inverse‐variance model was used to produce an overall estimated hazards ratio. Hazard ratios are shown with 95 per cent confidence intervals](BJS-103-1259-g006){#bjs10233-fig-0006}

Discussion {#bjs10233-sec-0017}
==========

The question addressed by this systematic review is whether follow‐up strategies involving more intensive monitoring, with more frequent investigation and/or additional methods of detection, lead to an improvement in overall survival. Meta‐analyses of the ORs and derived HRs from seven RCTs including 3325 patients showed no survival benefit from successively intensified monitoring policies. The authors of ten[2](#bjs10233-bib-0002){ref-type="ref"}, [3](#bjs10233-bib-0003){ref-type="ref"}, [4](#bjs10233-bib-0004){ref-type="ref"}, [16](#bjs10233-bib-0016){ref-type="ref"}, [17](#bjs10233-bib-0017){ref-type="ref"}, [20](#bjs10233-bib-0020){ref-type="ref"}, [24](#bjs10233-bib-0024){ref-type="ref"}, [25](#bjs10233-bib-0025){ref-type="ref"}, [27](#bjs10233-bib-0027){ref-type="ref"}, [30](#bjs10233-bib-0030){ref-type="ref"} of the 11 trials reported no survival benefit from more intensive monitoring. This could have been due to lack of power, but the meta‐analysis is consistent with the findings of individual studies. Three studies[4](#bjs10233-bib-0004){ref-type="ref"}, [24](#bjs10233-bib-0024){ref-type="ref"}, [26](#bjs10233-bib-0026){ref-type="ref"} that reported outcomes on quality of life found no differences with respect to this outcome.

A random‐effects model and, where possible, HRs were used to quantify outcomes, as the outcomes of interest occur over time. Owing to data limitations, ORs were used for some comparisons. Where it was possible to do both analyses, there was no difference in the conclusion. A limitation of this systematic review is that publication bias may have affected the observed outcomes as unpublished data, abstracts and presentations were not included. However, consideration of this possible bias would likely make a survival benefit even less plausible.

Intensive follow‐up was reported to show significantly improved survival by the authors of only one study[22](#bjs10233-bib-0022){ref-type="ref"}. It was attributed to reappearance of treatable residual disease after resection of rectal (as opposed to colonic) cancer. In exploratory subset analyses, other studies[2](#bjs10233-bib-0002){ref-type="ref"}, [4](#bjs10233-bib-0004){ref-type="ref"} showed a survival difference in favour of more intensive monitoring benefit where local recurrence of rectal cancer was found endoscopically.

Earlier meta‐analyses[1](#bjs10233-bib-0001){ref-type="ref"}, [35](#bjs10233-bib-0035){ref-type="ref"} suggested a favourable effect on survival. This was not found in the present meta‐analysis, which included larger and methodologically more robust trials reported in the past couple of years. These showed poorer survival in the more intensively screened groups, although the results were not significant individually. The survival results of this updated meta‐analysis show no benefit. Although not statistically significant, the point estimates consistently suggest an adverse effect on survival. What these later RCTs have in common is that they were multicentre studies run from trial centres. It is possible that the commitment of physicians involved in follow‐up has made a difference to outcomes in smaller institutional studies. Many of these patients will have had individualized treatment including systemic chemotherapy, but no overall benefit from monitoring and earlier detection has been shown in the meta‐analysis. This analysis gives a coherent and trustworthy, but disappointingly negative, message about the hoped‐for survival benefit of intensification of active monitoring after primary resection of colorectal cancer.
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